Document is current
Any future updates will be listed below
-
Authors
Belmer, Arnauld https://orcid.org/0000-0001-6640-5631
Depoortere, Ronan
Beecher, Kate
Newman-Tancredi, Adrian https://orcid.org/0000-0002-2923-5714
Bartlett, Selena E. https://orcid.org/0000-0002-1741-3958
-
Funding
Funding for this research was provided by:
Queensland University of Technology (PILOT, EQUIPMENT, SEED, EDGE)
Department of Health | National Health and Medical Research Council (GNT1146417)
- License Information
-
More Information
Article History
Received: 21 April 2022
Revised: 5 September 2022
Accepted: 9 September 2022
First Online: 4 October 2022
Competing interests
: ANT and RD are shareholders and employees of Neurolixis and have a proprietary interest in NLX-101 and NLX-112.
